<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2407-7-88</article-id><article-id pub-id-type="pmid">17524139</article-id><article-id pub-id-type="doi">10.1186/1471-2407-7-88</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Expression of CD80 and CD86 costimulatory molecules are potential markers for better survival in nasopharyngeal carcinoma</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Chang</surname><given-names>Cheng-Shyong</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>15120@cch.org.tw</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Chang</surname><given-names>Julia H</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>67842@cch.org.tw</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Hsu</surname><given-names>Nicholas C</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>99054@cch.org.tw</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Lin</surname><given-names>Hsuan-Yu</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>93687@cch.org.tw</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Chung</surname><given-names>Chih-Yuan</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>45413@cch.org.tw</email></contrib></contrib-group><aff id="I1"><label>1</label>Division of Hematology-Oncology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan</aff><aff id="I2"><label>2</label>Department of Pathology, Changhua Christian Hospital, Changhua, Taiwan</aff><aff id="I3"><label>3</label>Department of Medical Education and Research, Changhua Christian Hospital, Changhua, Taiwan</aff><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>24</day><month>5</month><year>2007</year></pub-date><volume>7</volume><fpage>88</fpage><lpage>88</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/7/88"/><history><date date-type="received"><day>14</day><month>12</month><year>2006</year></date><date date-type="accepted"><day>24</day><month>5</month><year>2007</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2007 Chang et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Chang et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Chang Cheng-Shyong 15120@cch.org.tw </dc:author><dc:title> Expression of CD80 and CD86 costimulatory molecules are potential markers for better survival in nasopharyngeal carcinoma </dc:title><dc:date>2007</dc:date><dcterms:bibliographicCitation>BMC Cancer 7(1): 88-. (2007)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2407(2007)7:1&#x0003c;88&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2407</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>B7 Costimulatory signal is essential to trigger T-cell activation upon the recognition of tumor antigens. This study examined the expression of B7-1 (CD80) and B7-2 (CD86) costimulatory molecules along with HLA-DR and the presence of infiltrating lymphocytes and dendritic cells to assess their significance in patients with nasopharyngeal carcinoma (NPC).</p></sec><sec sec-type="methods"><title>Methods</title><p>Expression of CD80, CD86, HLA-DR, S-100 protein and the presence of infiltrating lymphocytes and follicular dendritic reticulum cells were immunohistochemically examined on the paraffin-embedded tissue blocks from newly diagnosed NPC patients (n = 50). The results were correlated with clinical outcome of patients.</p></sec><sec><title>Results</title><p>CD80 and CD86 were each expressed in 10 of 50 cases in which they co-expressed in 9 cases. Univariate analysis revealed that patients with CD80/CD86 expression had significantly better overall survival than those without it (P = 0.017), but after adjustment for stage, nodal status, and treatment, the expression of CD80/CD86 did not significantly correlate with overall survival. Expression of HLA-DR and the presence of infiltrating lymphocytes and dendritic cells did not appear to have impact on the survival of patients.</p></sec><sec><title>Conclusion</title><p>Expression of CD80 and CD86 costimulatory molecules appears to be a marker of better survival in patient with NPC.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Nasopharyngeal carcinoma (NPC) is a neoplasm with high incidence in Southeast Asia, the Mediterranean basin, and North Africa. Early-stage NPC is usually treated with radiotherapy alone, and combination of chemotherapy is effective in the more advanced-stages of NPC [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B4">4</xref>]. Identification of a pathobiological correlate of clinical behavior of NPC represents a challenge. The development of such a test may improve the outcome of treatment as high-risk patients could benefit from early intervention and aggressive treatment.</p><p>B7 Costimulatory molecules are membrane-bound molecules which play a decisive role in the activation of T cells. This costimulatory pathway involves the interaction of two distinct B7 molecules, B7-1 (CD80) and B7-2 (CD86), which are transmembrane glycoprotein members of the Ig superfamily [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref>] expressed on antigen-presenting cells with their T cell counter receptors CD28 and CTLA-4 [<xref ref-type="bibr" rid="B8">8</xref>]. Interaction of B7:CD28 has been shown to provide a critical signal for T cell activation, while the absence of this signal results in T cell anergy [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>]. It is speculated that T cell anergy as the result of a paucity of B7 costimulatory molecules, which may permit the immune evasion of the cancer, is one of the mechanisms responsible for the poor immunogenicity of tumor cells. Experimental evidence has confirmed the expression of B7 costimulatory molecules in tumor cells of NPC [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>], it is therefore interesting to determine whether B7 costimulatory molecules are factors influencing the survival outcome of patients.</p><p>In the present study, we analyzed 50 NPC tissue samples to investigate the presence of CD80 and CD86 costimulatory molecules and establish their clinical significance in NPC. The significance of infiltrating cells (lymphocytic and dendritic cells) and HLA-DR expression in tumor cells were also examined in parallel and correlated with survival in patients with NPC.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patient selection and tissue specimens</title><p>Paraffin embedded tissue blocks (5&#x02013;7 &#x003bc;m) from biopsies of newly diagnosed NPC patients between January 2001 and December 2002 were retrieved from the Department of Pathology, Changhua Christian Hospital, Taiwan (n = 50) with informed consent according to guidelines of the Changhua Christian Hospital Institution Review Board. All patients were staged according to the 1997 American Joint Committee on Cancer tumor-node-metastasis staging systems [<xref ref-type="bibr" rid="B12">12</xref>]. The pathological stage and nodal status were obtained from the primary pathology reports. Slides from tumors were reviewed by two pathologists to define the histological grading. The survival data were either obtained from the cancer registry of Changhua Christian Hospital or collected from the patients' attending physicians. 42 of the 50 patients received concurrent chemoradiotherapy consisting of cisplatin and fluorouracil. Five patients (T1-2 N0) along with three patients with T stage of 3&#x02013;4 refused chemotherapy were treated with radiation alone. The median follow-up period was 56 months (range, 1&#x02013;73 months).</p></sec><sec><title>Immunohistochemical staining</title><p>Blocks were sectioned and put on poly-1-lysine coated slides. After deparaffinized, the section was treated with 3% H<sub>2</sub>O<sub>2 </sub>in methanol. The sections were then hydrated through gradient alcohol and PBS. Slides were placed in 10 mM citrate buffer and heated for 20 minutes in a 700-W microwave oven at 100&#x000b0;C in PBS. Slides from each case were exposed to 1:200 dilution of anti-CD80 monoclonal antibody (Santa Cruz Biotechnology, USA) and 1:100 dilution of anti-CD86 polyclonal antibody (Immunotech, Marseille, France) for 30 minutes at room temperature followed by incubation with a PicTure Polymer Kits for 20 minutes (Zymed, South San Francisco, USA). The sections were thoroughly washed with PBS between steps. The sites of peroxidase were visualized with 3,3'-diaminobenzidine tetrahydrochloride. Hematoxylin was used for counterstaining. The percentage of immunoreactivity in the tumor cells was scored as 0 to +2. Immunoreactivity in &#x0003c;10% of tumor cells was considered as aberrant expression (-), 10&#x02013;50% (+1), and &#x0003e;50% (+2). All fields in the sections were examined. Investigator-bias was avoided by two investigators independently scoring coded sections. Furthermore, CD80 and CD86 positive samples were repeated to ensure that no false positive results occurred in the experiment.</p><p>Same steps and scoring systems were carried out with the following monoclonal and polyclonal antibodies to address the expression of HLA-DR and the presence of infiltrating lymphocytes and dendritic cells: anti-CD45R0, anti-CD20, and anti-Follicular Dendritic Reticulum Cells (all from Dakocytomation, Denmark); anti-HLA Class II (DR) and anti-S-100 (both from Novocastra Laboratories, UK).</p></sec><sec><title>Statistical analysis</title><p>Survival curves in accordance with various potential prognostic indicators were produced. Survival was defined as the time between date of diagnosis and date of death. Patients still alive at the end of the study were censored at the date of last follow-up. Sections scored as +1 and +2 were identified as positive staining to decrease the number of variables for statistical purpose. Survival rate was computed using standard Kaplan-Meier methods, and the difference in survival curves was analyzed by the log-rank test. Independent prognostic factors were analyzed by the Cox proportional hazards regression model. Variables in the model included T stage, nodal (N) stage, and treatment (radiotherapy or concurrent chemoradiotherapy). A P value of less than 0.05 was considered to indicate statistical significance.</p></sec></sec><sec><title>Results and discussion</title><sec><title>CD80/CD86 expression</title><p>Regardless of stage and histological type, CD80 and CD86 were each expressed in 10 of 50 cases in which they co-expressed in 9 cases. Expression of CD80 and CD86 were classified as a group to reduce the number of prognostic variables as 9 patients had overlapping expression. Positive membrane and occasional cytoplasmic staining of CD80/CD86 was observed in 11 of the 50 patients (Figure <xref ref-type="fig" rid="F1">1</xref>, Table <xref ref-type="table" rid="T1">1</xref>). CD80/CD86 expression was not noticed in normal nasopharyngeal mucosal epithelia. Abnormal nasopharyngeal epithelia were hardly present in our biopsies.</p></sec><sec><title>Uni-and multivariate analyses for prognostic factors</title><p>The Univariate analysis revealed that there was a significant association between expression of either CD80 or CD86 and clinical outcome in terms of survival (P = 0.017) (Table <xref ref-type="table" rid="T2">2</xref>). The Kaplan-Meier survival curves of the 50 NPC patients were plotted into 2 groups according to immunostaining results with either CD80/CD86 positive or negative (Figure <xref ref-type="fig" rid="F2">2</xref>). Due to the limited number of patients, in the multivariate analysis which incorporated independent prognostic factors of T stage, N stage, and treatment (concurrent chemoradiotherapy vs. radiotherapy alone), we found that CD80/86 expression was not significant with regard to survival (Table <xref ref-type="table" rid="T3">3</xref>). No association was observed between CD80/86 expression and the infiltration of T-cells and dendritic cells (Table <xref ref-type="table" rid="T4">4</xref>).</p></sec><sec><title>T, B, and dendritic cell infiltration and HLA-DR expression in NPC tissue sections</title><p>Subpopulations of infiltrating lymphocytes in NPC were identified using anti-T (CD45R0) and anti-B (CD20) cell antibodies. Follicular dendritic reticulum cells, S-100 protein which marks infiltrating dendritic cells, along with tumor HLA-DR (Figure <xref ref-type="fig" rid="F3">3</xref>) expression were also identified in this study. However, none were statistically significant for survival (Table <xref ref-type="table" rid="T2">2</xref>).</p></sec></sec><sec><title>Conclusion</title><p>Studies have described the presence of B7 costimulatory molecules in tumor cells of NPC, and the corresponding counter-receptor, CD28, in lymphoid cells, implying some communication between T cells and carcinoma cells in the microenvironment of NPC [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. These data suggest certain level of immune response directed at the NPC tumor cells with the presence of B7 costimulatory molecules in tumor cells of NPC and the vast number of infiltrating T cells. This phenomenon might explain why in the majority of NPC patients, the large prevalence of T cells in the neoplastic tissue does not have any prognostic significance. The presence of B7 costimulatory molecules is essential for the activation of T cells.</p><p>Our experimental evidence supports the finding that in a subset of NPC patients, tumor cells indeed express B7 costimulatory molecules. CD80 and CD86 were each expressed in 10 of 50 of our NPC cases in which they co-expressed in 9 cases. Due to the limited number of NPC cases, statistical conclusions which correlate the expression of CD80/86 with survival can not be drawn in the multivariate analysis in this study. Additional studies with larger number of patients are needed to confirm this finding.</p><p>However, this study demonstrated the presence of B7 costimulatory molecules in the neoplastic tissue of NPC and their possible prognostic importance. It is the first to show a significant association between expression of CD80/CD86 and a favorable outcome in patients with NPC by univariate analysis.</p><p>With a relatively small group of patients, our data suggested that neither expression of HLA-DR, the presence of infiltrating dendritic cells (follicular and S-100(+) interdigitating), nor the prevalence of lymphocytes in the neoplastic tissue had any prognostic significance for survival in patients with NPC. However, we can not rule out that with large number of patients, the prognostic factors might have been significant on the basis of this report.</p><p>The absence or low level expression of B7 costimulatory molecules by malignant cells is thought to represent one mechanism by which they escape immunosurveillance. Recently, CD80 expression has been demonstrated to be closely associated with decreased tumorigenicity in oral squamous carcinoma, suggesting that inadequate CD80 expression during early oral squamous cell carcinoma formation may contribute to the escape of tumors from the immune system [<xref ref-type="bibr" rid="B13">13</xref>]. The fact that 9 of the 11 (82%) CD80/86 positive patients were in T stage of 1&#x02013;2 provide indirect evidence that expression of CD80/86 may serve as a marker for decreased tumorigenicity during early development of NPC.</p><p>The question of whether expression of B7 costimulatory molecules represent enhanced immunity against tumor has important implications with regard to the prognosis and treatment of NPC. The demonstration in this study which addresses the presence of B7 costimulatory molecules in the neoplastic tissue of NPC and their possible role in the prognosis of this disease is important. It should be noted that B7 expression could be widely determined on routinely processed, paraffin-embedded tissues for prognostic evaluation in NPC cases, whereas the quantification of plasma EBV DNA [<xref ref-type="bibr" rid="B14">14</xref>] can only be reliably performed for the purpose of clinical evaluation in sophisticated centers. Finally, integration of multiple markers and tools through use of statistical modeling should improve our ability to identify high-risk patients who may benefit from refined treatment strategies.</p></sec><sec><title>Abbreviations</title><p>NPC &#x02013; nasopharyngeal carcinoma</p><p>EBV &#x02013; Epstein-Barr virus</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>CSC designed the study and drafted the manuscript. JHC carried out the immunohistochemical staining. NCH participated in the statistical analysis. HYL helped to design the study. CYC participated in the coordination of the study. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/7/88/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We thank Yu-Jun Chang for technical advice and all the NPC patients who joined this study. This project was supported by Grant No. 9250 from Department of Medical Education and Research, Changhua Christian Hospital, Taiwan.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>JC</given-names></name><name><surname>Jan</surname><given-names>JS</given-names></name><name><surname>Hsu</surname><given-names>CY</given-names></name><name><surname>Jiang</surname><given-names>RS</given-names></name><name><surname>Wang</surname><given-names>WY</given-names></name></person-group><article-title>Outpatient weekly neoadjuvant chemotherapy followed by radiotherapy for advanced nasopharyngeal carcinoma: high complete response and low toxicity rates</article-title><source>Br J Cancer</source><year>2003</year><volume>88</volume><fpage>187</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">12610501</pub-id><pub-id pub-id-type="doi">10.1038/sj.bjc.6600716</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>JC</given-names></name><name><surname>Jan</surname><given-names>JS</given-names></name><name><surname>Hsu</surname><given-names>CY</given-names></name><name><surname>Liang</surname><given-names>WM</given-names></name><name><surname>Jiang</surname><given-names>RS</given-names></name><name><surname>Wang</surname><given-names>WY</given-names></name></person-group><article-title>Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><fpage>631</fpage><lpage>637</lpage><pub-id pub-id-type="pmid">12586799</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2003.06.158</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>JC</given-names></name><name><surname>Jan</surname><given-names>JS</given-names></name><name><surname>Chen</surname><given-names>KY</given-names></name><name><surname>Hsu</surname><given-names>CY</given-names></name><name><surname>Liang</surname><given-names>WM</given-names></name><name><surname>Wang</surname><given-names>WY</given-names></name></person-group><article-title>Outpatient weekly 24-hour infusional adjuvant chemotherapy of cisplatin, 5-fluorouracil, and leucovorin for high-risk nasopharyngeal carcinoma</article-title><source>Head Neck</source><year>2003</year><volume>25</volume><fpage>438</fpage><lpage>450</lpage><pub-id pub-id-type="pmid">12784235</pub-id><pub-id pub-id-type="doi">10.1002/hed.10238</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Al-Sarraf</surname><given-names>M</given-names></name><name><surname>LeBlanc</surname><given-names>M</given-names></name><name><surname>Giri</surname><given-names>PG</given-names></name><name><surname>Fu</surname><given-names>KK</given-names></name><name><surname>Cooper</surname><given-names>J</given-names></name><name><surname>Vuong</surname><given-names>T</given-names></name><name><surname>Forastiere</surname><given-names>AA</given-names></name><name><surname>Adams</surname><given-names>G</given-names></name><name><surname>Sakr</surname><given-names>WA</given-names></name><name><surname>Schuller</surname><given-names>DE</given-names></name><etal></etal></person-group><article-title>Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099</article-title><source>J Clin Oncol</source><year>1998</year><volume>16</volume><fpage>1310</fpage><lpage>1317</lpage><pub-id pub-id-type="pmid">9552031</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Azuma</surname><given-names>M</given-names></name><name><surname>Ito</surname><given-names>D</given-names></name><name><surname>Yagita</surname><given-names>H</given-names></name><name><surname>Okumura</surname><given-names>K</given-names></name><name><surname>Phillips</surname><given-names>JH</given-names></name><name><surname>Lanier</surname><given-names>LL</given-names></name><name><surname>Somoza</surname><given-names>C</given-names></name></person-group><article-title>B70 antigen is a second ligand for CTLA-4 and CD28</article-title><source>Nature</source><year>1993</year><volume>366</volume><fpage>76</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">7694153</pub-id><pub-id pub-id-type="doi">10.1038/366076a0</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>GJ</given-names></name><name><surname>Gribben</surname><given-names>JG</given-names></name><name><surname>Boussiotis</surname><given-names>VA</given-names></name><name><surname>Ng</surname><given-names>JW</given-names></name><name><surname>Restivo</surname><given-names>VA</given-names><suffix>Jr</suffix></name><name><surname>Lombard</surname><given-names>LA</given-names></name><name><surname>Gray</surname><given-names>GS</given-names></name><name><surname>Nadler</surname><given-names>LM</given-names></name></person-group><article-title>Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation</article-title><source>Science</source><year>1993</year><volume>262</volume><fpage>909</fpage><lpage>911</lpage><pub-id pub-id-type="pmid">7694363</pub-id><pub-id pub-id-type="doi">10.1126/science.7694363</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>GJ</given-names></name><name><surname>Freedman</surname><given-names>AS</given-names></name><name><surname>Segil</surname><given-names>JM</given-names></name><name><surname>Lee</surname><given-names>G</given-names></name><name><surname>Whitman</surname><given-names>JF</given-names></name><name><surname>Nadler</surname><given-names>LM</given-names></name></person-group><article-title>B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells</article-title><source>J Immunol</source><year>1989</year><volume>143</volume><fpage>2714</fpage><lpage>2722</lpage><pub-id pub-id-type="pmid">2794510</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lenschow</surname><given-names>DJ</given-names></name><name><surname>Walunas</surname><given-names>TL</given-names></name><name><surname>Bluestone</surname><given-names>JA</given-names></name></person-group><article-title>CD28/B7 system of T cell costimulation</article-title><source>Annu Rev Immunol</source><year>1996</year><volume>14</volume><fpage>233</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">8717514</pub-id><pub-id pub-id-type="doi">10.1146/annurev.immunol.14.1.233</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname><given-names>FA</given-names></name><name><surname>McArthur</surname><given-names>JG</given-names></name><name><surname>Gross</surname><given-names>JA</given-names></name><name><surname>Raulet</surname><given-names>DH</given-names></name><name><surname>Allison</surname><given-names>JP</given-names></name></person-group><article-title>CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones</article-title><source>Nature</source><year>1992</year><volume>356</volume><fpage>607</fpage><lpage>609</lpage><pub-id pub-id-type="pmid">1313950</pub-id><pub-id pub-id-type="doi">10.1038/356607a0</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agathanggelou</surname><given-names>A</given-names></name><name><surname>Niedobitek</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Nicholls</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>W</given-names></name><name><surname>Young</surname><given-names>LS</given-names></name></person-group><article-title>Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells</article-title><source>Am J Pathol</source><year>1995</year><volume>147</volume><fpage>1152</fpage><lpage>1160</lpage><pub-id pub-id-type="pmid">7573360</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>KF</given-names></name><name><surname>Chan</surname><given-names>SH</given-names></name><name><surname>Loh</surname><given-names>KS</given-names></name><name><surname>Chong</surname><given-names>SM</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Yeoh</surname><given-names>KH</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name></person-group><article-title>Increased production of interferon-gamma by tumour infiltrating T lymphocytes in nasopharyngeal carcinoma: indicative of an activated status</article-title><source>Cancer Lett</source><year>1999</year><volume>140</volume><fpage>93</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">10403546</pub-id><pub-id pub-id-type="doi">10.1016/S0304-3835(99)00056-7</pub-id></citation></ref><ref id="B12"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Fleming</surname><given-names>ID</given-names></name><name><surname>Cooper</surname><given-names>JS</given-names></name><name><surname>Henson</surname><given-names>DE</given-names></name><name><surname>Hutter</surname><given-names>RV</given-names></name><name><surname>Kennedy</surname><given-names>BJ</given-names></name><name><surname>Murphy</surname><given-names>GP</given-names></name><name><surname>O'Sullivan</surname><given-names>B</given-names></name><name><surname>Sobin</surname><given-names>LH</given-names></name><name><surname>Yarbro</surname><given-names>JW</given-names></name><collab>Eds</collab></person-group><source>AJCC cancer staging manual</source><year>1997</year><edition>5</edition><publisher-name>Philadelphia: Lippincott-Raven</publisher-name><fpage>31</fpage><lpage>39</lpage></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>GR</given-names></name><name><surname>Wen</surname><given-names>J</given-names></name></person-group><article-title>Endogenous expression of CD80 co-stimulatory molecules facilitates in vivo tumor regression of oral squamous carcinoma</article-title><source>Anticancer Res</source><year>2006</year><volume>26</volume><fpage>4093</fpage><lpage>4101</lpage><pub-id pub-id-type="pmid">17201120</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>JC</given-names></name><name><surname>Wang</surname><given-names>WY</given-names></name><name><surname>Chen</surname><given-names>KY</given-names></name><name><surname>Wei</surname><given-names>YH</given-names></name><name><surname>Liang</surname><given-names>WM</given-names></name><name><surname>Jan</surname><given-names>JS</given-names></name><name><surname>Jiang</surname><given-names>RS</given-names></name></person-group><article-title>Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma</article-title><source>N Engl J Med</source><year>2004</year><volume>350</volume><fpage>2461</fpage><lpage>2470</lpage><pub-id pub-id-type="pmid">15190138</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa032260</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><fig position="float" id="F1"><label>Figure 1</label><caption><p>Immunohistochemical staining for (A) CD 80<sup>- </sup>and (B) CD80 (+1) in undifferentiated carcinoma of the nasopharynx (&#x000d7;400); (C) CD 86<sup>- </sup>in non-keratinizing squamous cell and (D) CD86 (+2) in undifferentiated carcinoma of the nasopharynx (&#x000d7;400).</p></caption><graphic xlink:href="1471-2407-7-88-1"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>Kaplan-Meier survival curves based on expression of CD80/CD86 for patients with nasopharyngeal carcinoma.</p></caption><graphic xlink:href="1471-2407-7-88-2"/></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p>Positive membrane staining of HLA-DR in undifferentiated carcinoma, 400 &#x000d7; (A); negative staining of HLA-DR in carcinoma cellsand dispersed lymphocytes with HLA-DR expression, 400 &#x000d7; (B).</p></caption><graphic xlink:href="1471-2407-7-88-3"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Characteristics of 50 patients with nasopharyngeal carcinoma</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Characteristics</bold></td><td></td><td align="center" colspan="2">Overall</td><td align="center" colspan="2">CD80/86(+)</td></tr></thead><tbody><tr><td></td><td></td><td align="center">No.</td><td align="center">%</td><td align="center">No.</td><td align="center">%</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left" colspan="6"><bold>Age, years</bold></td></tr><tr><td></td><td align="left">Range</td><td align="center">38&#x02013;83</td><td></td><td align="center">38&#x02013;78</td><td></td></tr><tr><td></td><td align="left">Median</td><td align="center">50</td><td></td><td align="center">46</td><td></td></tr><tr><td></td><td align="left">Mean</td><td align="center">53</td><td></td><td align="center">50</td><td></td></tr><tr><td align="left" colspan="6"><bold>Sex</bold></td></tr><tr><td></td><td align="left">Male</td><td align="center">42</td><td align="center">84</td><td align="center">10</td><td align="center">91</td></tr><tr><td></td><td align="left">Female</td><td align="center">8</td><td align="center">16</td><td align="center">1</td><td align="center">9</td></tr><tr><td align="left" colspan="6"><bold>Pathology (WHO classification)</bold></td></tr><tr><td></td><td align="left">Type I</td><td align="center">--</td><td></td><td align="center">--</td><td></td></tr><tr><td></td><td align="left">Type II</td><td align="center">35</td><td align="center">70</td><td align="center">6</td><td align="center">55</td></tr><tr><td></td><td align="left">Type III</td><td align="center">15</td><td align="center">30</td><td align="center">5</td><td align="center">45</td></tr><tr><td align="left" colspan="6"><bold>T Stage (1997 AJCC)</bold></td></tr><tr><td></td><td align="left">T1 or T2</td><td align="center">32</td><td align="center">64</td><td align="center">9</td><td align="center">82</td></tr><tr><td></td><td align="left">T3 or T4</td><td align="center">18</td><td align="center">36</td><td align="center">2</td><td align="center">18</td></tr><tr><td align="left" colspan="6"><bold>N Stage (1997AJCC)</bold></td></tr><tr><td></td><td align="left">N0 or N1</td><td align="center">24</td><td align="center">48</td><td align="center">6</td><td align="center">55</td></tr><tr><td></td><td align="left">N2</td><td align="center">17</td><td align="center">34</td><td align="center">3</td><td align="center">27</td></tr><tr><td></td><td align="left">N3</td><td align="center">9</td><td align="center">18</td><td align="center">2</td><td align="center">18</td></tr><tr><td align="left" colspan="6"><bold>Overall Stage (1997 AJCC)</bold></td></tr><tr><td></td><td align="left">I</td><td align="center">5</td><td align="center">10</td><td align="center">3</td><td align="center">27</td></tr><tr><td></td><td align="left">II</td><td align="center">10</td><td align="center">20</td><td align="center">3</td><td align="center">27</td></tr><tr><td></td><td align="left">III</td><td align="center">13</td><td align="center">26</td><td align="center">2</td><td align="center">18</td></tr><tr><td></td><td align="left">IV</td><td align="center">22</td><td align="center">44</td><td align="center">3</td><td align="center">27</td></tr><tr><td align="left" colspan="6"><bold>Treatment</bold></td></tr><tr><td></td><td align="left">Radiotherapy alone</td><td align="center">8</td><td align="center">16</td><td align="center">2</td><td align="center">18</td></tr><tr><td></td><td align="left">Concurrent Chemoradiotherapy</td><td align="center">42</td><td align="center">84</td><td align="center">9</td><td align="center">82</td></tr><tr><td align="left" colspan="6"><bold>Status</bold></td></tr><tr><td></td><td align="left">Death</td><td align="center">16</td><td align="center">32</td><td align="center">0</td><td align="center">0</td></tr><tr><td></td><td align="left">Alive</td><td align="center">34</td><td align="center">68</td><td align="center">11</td><td align="center">100</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: WHO, World Health Organization; AJCC, American Joint Committee on Cancer; FDRC, Follicular Dendritic Reticulum Cells</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Univariate analysis for overall survival of patients with nasopharyngeal carcinoma</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" colspan="7">Kaplan-Meier Survival Rate</td></tr></thead><tbody><tr><td></td><td></td><td></td><td></td><td align="center" colspan="2">Censored</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2"><hr></hr></td><td></td></tr><tr><td></td><td></td><td align="center">Total</td><td align="center">Dead</td><td align="center">N</td><td align="center">%</td><td align="center">P-value</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td></td><td align="left">Overall</td><td align="center">50</td><td align="center">16</td><td align="center">34</td><td align="center">68.0</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">T</td><td align="left">Negative</td><td align="center">7</td><td align="center">3</td><td align="center">4</td><td align="center">57.1</td><td align="center">0.543</td></tr><tr><td></td><td align="left">Positive</td><td align="center">43</td><td align="center">13</td><td align="center">30</td><td align="center">69.8</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">B</td><td align="left">Negative</td><td align="center">9</td><td align="center">4</td><td align="center">5</td><td align="center">55.6</td><td align="center">0.253</td></tr><tr><td></td><td align="left">Positive</td><td align="center">41</td><td align="center">12</td><td align="center">29</td><td align="center">70.7</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">FDC</td><td align="left">Negative</td><td align="center">20</td><td align="center">8</td><td align="center">12</td><td align="center">60.0</td><td align="center">0.286</td></tr><tr><td></td><td align="left">Positive</td><td align="center">30</td><td align="center">8</td><td align="center">22</td><td align="center">73.3</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">CD80*</td><td align="left">Negative</td><td align="center">40</td><td align="center">16</td><td align="center">24</td><td align="center">60.0</td><td align="center">0.025</td></tr><tr><td></td><td align="left">Positive</td><td align="center">10</td><td align="center">0</td><td align="center">10</td><td align="center">100.0</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">CD86*</td><td align="left">Negative</td><td align="center">40</td><td align="center">16</td><td align="center">24</td><td align="center">60.0</td><td align="center">0.025</td></tr><tr><td></td><td align="left">Positive</td><td align="center">10</td><td align="center">0</td><td align="center">10</td><td align="center">100.0</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">CD80/86*</td><td align="left">Negative</td><td align="center">39</td><td align="center">16</td><td align="center">23</td><td align="center">59.0</td><td align="center">0.017</td></tr><tr><td></td><td align="left">Positive</td><td align="center">11</td><td align="center">0</td><td align="center">11</td><td align="center">100.0</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">HLA1DR</td><td align="left">Negative</td><td align="center">15</td><td align="center">7</td><td align="center">8</td><td align="center">53.3</td><td align="center">0.167</td></tr><tr><td></td><td align="left">Positive</td><td align="center">35</td><td align="center">9</td><td align="center">26</td><td align="center">74.3</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">S100</td><td align="left">Negative</td><td align="center">20</td><td align="center">7</td><td align="center">13</td><td align="center">65.0</td><td align="center">0.654</td></tr><tr><td></td><td align="left">Positive</td><td align="center">30</td><td align="center">9</td><td align="center">21</td><td align="center">70.0</td><td></td></tr></tbody></table><table-wrap-foot><p>P-value by Log-rank test</p><p>Follow-up time: from diagnosis date till death/2-15-2007</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Multivariate analysis of clinicopathologic factors for overall survival of patients with nasopharyngeal carcinoma</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td></td><td align="center">Total</td><td align="center">Dead</td><td align="center">%</td><td align="center">HR</td><td align="center" colspan="3">95% C.I. for HR</td><td align="center">P-value</td></tr></thead><tbody><tr><td align="left">CD80/86</td><td align="left">Negative</td><td align="center">39</td><td align="center">16</td><td align="center">41.0</td><td align="center">1.000</td><td></td><td></td><td></td><td align="center">0.968</td></tr><tr><td></td><td align="left">Positive</td><td align="center">11</td><td align="center">0</td><td align="center">0.0</td><td align="center">0.000</td><td align="left">0.000</td><td align="left">-</td><td align="center">6.853E+282</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">T Stage</td><td align="left">1 or 2</td><td align="center">32</td><td align="center">7</td><td align="center">21.9</td><td align="center">1.000</td><td></td><td></td><td></td><td align="center">0.050</td></tr><tr><td></td><td align="left">3 or 4</td><td align="center">18</td><td align="center">9</td><td align="center">50.0</td><td align="center">2.892</td><td align="left">1.001</td><td align="left">-</td><td align="left">8.353</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">N Stage</td><td align="left">0 or 1</td><td align="center">24</td><td align="center">5</td><td align="center">20.8</td><td align="center">1.000</td><td></td><td></td><td></td><td align="center">0.065</td></tr><tr><td></td><td align="left">2 or 3</td><td align="center">26</td><td align="center">11</td><td align="center">42.3</td><td align="center">2.830</td><td align="left">0.938</td><td align="left">-</td><td align="left">8.539</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Treatment</td><td align="left">RT</td><td align="center">8</td><td align="center">1</td><td align="center">12.5</td><td align="center">1.000</td><td></td><td></td><td></td><td align="center">0.193</td></tr><tr><td></td><td align="left">CCRT</td><td align="center">42</td><td align="center">15</td><td align="center">35.7</td><td align="center">3.979</td><td align="left">0.497</td><td align="left">-</td><td align="left">31.870</td><td></td></tr></tbody></table><table-wrap-foot><p>HR: Hazard Ratio</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Association of CD80/86 expression and infiltration of T-cell/Dendritic cells in nasopharyngeal carcinoma</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td></td><td align="center" colspan="4">CD80/86</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="4"><hr></hr></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td align="center" colspan="2">Negative (n = 39)</td><td align="center" colspan="2">Positive (n = 11)</td><td align="center" colspan="2">Total (n = 50)</td><td align="center">&#x003a6;</td><td align="center">P-value</td></tr><tr><td></td><td></td><td colspan="2"><hr></hr></td><td colspan="4"><hr></hr></td><td></td><td></td></tr><tr><td></td><td></td><td align="center">N</td><td align="center">%</td><td align="center">N</td><td align="center">%</td><td align="center">N</td><td align="center">%</td><td></td><td></td></tr></thead><tbody><tr><td align="left">T</td><td align="left">Negative</td><td align="center">6</td><td align="center">15.4</td><td align="center">1</td><td align="center">9.1</td><td align="center">7</td><td align="center">14.0</td><td align="center">0.075</td><td align="center">1.000</td></tr><tr><td></td><td align="left">Positive</td><td align="center">33</td><td align="center">84.6</td><td align="center">10</td><td align="center">90.9</td><td align="center">43</td><td align="center">86.0</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">FDC</td><td align="left">Negative</td><td align="center">13</td><td align="center">33.3</td><td align="center">7</td><td align="center">63.6</td><td align="center">20</td><td align="center">40.0</td><td align="center">-0.256</td><td align="center">0.090</td></tr><tr><td></td><td align="left">Positive</td><td align="center">26</td><td align="center">66.7</td><td align="center">4</td><td align="center">36.4</td><td align="center">30</td><td align="center">60.0</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">S-100</td><td align="left">Negative</td><td align="center">16</td><td align="center">41.0</td><td align="center">4</td><td align="center">36.4</td><td align="center">20</td><td align="center">40.0</td><td align="center">0.039</td><td align="center">1.000</td></tr><tr><td></td><td align="left">Positive</td><td align="center">23</td><td align="center">59.0</td><td align="center">7</td><td align="center">63.6</td><td align="center">30</td><td align="center">60.0</td><td></td><td></td></tr></tbody></table><table-wrap-foot><p>P-value by Fisher's Exact Test</p><p>&#x003a6;: Phi correlation coefficient</p></table-wrap-foot></table-wrap></sec></back></article> 